Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock
Louis Navellier's strategy identifies high-potential stocks with eight fundamental rules, and Alnylam Pharmaceuticals (ALNY) perfectly fits the screen with 82.57% revenue growth, 443% EPS growth, and…
Read the full articleYou might also wanna read
Thursday’s Stock Market Winners and Losers: Alnylam Pharmaceuticals (ALNY) Jumps 18% as AstraZeneca (AZN) Plunges
Alnylam Pharmaceuticals (ALNY) surges 18% in premarket trading while AstraZeneca (AZN) drops 9% on failed trial. See Thursday's biggest stoc
Agenus (NASDAQ:AGEN) Stock Rockets 59% Premarket—But Its $340 Million Lifeline Could Nearly Triple the Share Count
New York, July 13, 2026, 09:09 EDT Agenus Inc. (NASDAQ:AGEN) surged 59.4% to $5.34 in premarket trading on Monday after agreeing to an $85 m
Broadcom (NASDAQ: AVGO), Micron (NASDAQ: MU), And IonQ (NYSE: IONQ) Lead The Pack As Top Hypergrowth Tech Stocks
Three technology companies are standing out as hypergrowth investment opportunities, each posting revenue expansion that far outpaces the br
Agenus Stock Soars 83%, but $255 Million of Its $340 Million Lifeline Is Still Conditional
NEW YORK, July 14, 2026, 04:31 (EDT) Agenus Inc. (NASDAQ:AGEN) shares closed 82.7% higher at $6.12 on Monday after the cancer-drug developer
Agenus (AGEN) Stock Jumps 13% After Securing $340M Financing Package
Agenus (AGEN) stock surged 13% premarket after securing $85M in financing with potential for $340M total to fund cancer trials through 2031.
RPG Life Sciences Launches Naprosyn ES in India; Firm Reports 14% Net Profit Growth
RPG Life Sciences enters an exclusive marketing agreement with Archerchem to launch Naprosyn ES, a value-added pharmaceutical combination ta
Comments
Sign in to join the conversation.
No comments yet. Be the first.